# Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk

Study · id `cardio:ct-nct07374718` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07374718](<https://clinicaltrials.gov/study/NCT07374718>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07374718

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 468 participants.

## Technical summary

Registry record NCT07374718. Randomized; no masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2028-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 468 participants (planned count; ClinicalTrials.gov record NCT07374718, source copy `cardio:ctgov-nct07374718-2026-01-29`, retrieved 2026-10-26)
- Planned start: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT07374718, source copy `cardio:ctgov-nct07374718-2026-01-29`, retrieved 2026-10-26)
- Primary completion: 2028-12-30 (anticipated) (ClinicalTrials.gov record NCT07374718, source copy `cardio:ctgov-nct07374718-2026-01-29`, retrieved 2026-10-26)
- Completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT07374718, source copy `cardio:ctgov-nct07374718-2026-01-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07374718, source copy `cardio:ctgov-nct07374718-2026-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07374718-2026-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
- Condition: Acute Coronary Syndrome (ACS)
- Condition: High Bleeding Risk(HBR)
- Condition: Coronary Artery Disease (CAD)
- Intervention (Device): IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy
- Intervention (Device): Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Lead sponsor: Shenyang Northern Hospital
- Lead sponsor class: OTHER
- Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Shenyang Northern Hospital (`cardio:org-shenyang-northern-hospital`)
- Registry lists this organization as a collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital (`cardio:org-chinese-academy-of-medical-sciences-fuwai-hospital`)

## Provenance

Content hash: a89884a87c42cb3f33d7e88c95bc21376a66b4693c23513da98a0f5ebc4e5bd8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
